ACAD


Company Update (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc. Announces FDA Priority Review of NUPLAZID New Drug Application for Parkinson’s Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous …

Monday Morning Market Insights: MannKind Corporation (MNKD), Seadrill Ltd (SDRL), Chipotle Mexican Grill, Inc. (CMG), ACADIA Pharmaceuticals Inc. (ACAD)

MannKind Corporation (NASDAQ:MNKD) fell 6.65% in pre-market trading down to $3.

Biotech Beat: RXi Pharmaceuticals Corp (RXII), ACADIA Pharmaceuticals Inc. (ACAD), Valeant Pharmaceuticals Intl Inc (VRX)

By Terry Chrisomalis RXi Pharmaceuticals Corp On August 31, 2015 RXi Pharmaceuticals Corp (NASDAQ:RXII) announced that the 30-day review period for its IND of RXI-109 …

J.P. Morgan Weighs in on ACADIA Pharmaceuticals Inc. as Nuplazid NDA in PDP Submitted

Morgan analyst Cory Kasimov weighed in today with his views on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), following the news of the much anticipated NDA submission of Nuplazid …

Needham’s Alan Carr Reiterates Buy on ACADIA Pharmaceuticals Inc. Following Nuplazid NDA Submission

In a research report released Thursday, Needham analyst Alan Carr reiterated a Buy rating on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a price …

Thursday Morning Pre-Market Insights: Tesla Motors Inc (TSLA), Seadrill Ltd (SDRL), ACADIA Pharmaceuticals Inc. (ACAD), Geron Corporation (GERN)

Tesla Motors Inc (NASDAQ:TSLA) is up 2.56% in pre-market trading to $254.

Stock Update (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc. Submits New Drug Application for NUPLAZID

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous …

Analysts Bullish on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Following Investor Meeting

Analysts weighed in on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with bullish sentiments following the company’s investor meeting this week.

Cowen Reiterates Outperform on ACADIA Pharmaceuticals Inc. Following Investor Meeting with Management

In a research report released Thursday, Cowen analyst Ritu Baral reiterated an Outperform rating on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a price …

Needham Raises Price Target for ACADIA Pharmaceuticals Inc. (ACAD) Ahead of NDA Submission

In a research report released Friday, Needham analyst Alan Carr reiterated a Buy rating on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and raised the …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts